Sage Therapeutics, Inc.
NASDAQ:SAGE
8.68 (USD) • At close July 31, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | Sage Therapeutics, Inc. | 
| Symbool | SAGE | 
| Munteenheid | USD | 
| Prijs | 8.68 | 
| Beurswaarde    |  544,942,552 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 4.62 - 9.36 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. Barry E. Greene | 
| Website | https://www.sagerx.com | 
An error occurred while fetching data.
Over Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)






